Adma Biologics Inc ADMA
Dividend Summary
There have not been any declared dividends recently.
| Summary | Previous dividend | Next dividend |
|---|---|---|
| Status | – | – |
| Type | – | – |
| Per share | – | – |
| Declaration date | – | – |
| Ex-div date | – | – |
| Pay date | – | – |
Enter the number of Adma Biologics Inc shares you hold and we'll calculate your dividend payments:
Sign up for Adma Biologics Inc and we'll email you the dividend information when they declare.
Add Adma Biologics Inc to receive free notifications when they declare their dividends.
Your account is set up to receive Adma Biologics Inc notifications.
| Status | Type | Decl. date | Ex-div date | Pay date | Decl. Currency | Forecast amount | Decl. amount | Accuracy |
|---|---|---|---|---|---|---|---|---|
| There are no Adma Biologics Inc dividends. | ||||||||
| Year | Amount | Change |
|---|---|---|
| 2006 | 0.0c | — |
| 2007 | 0.0c | 0% |
| 2008 | 0.0c | 0% |
| 2009 | 0.0c | 0% |
| 2010 | 0.0c | 0% |
| 2011 | 0.0c | 0% |
| 2012 | 0.0c | 0% |
| 2013 | 0.0c | 0% |
| 2014 | 0.0c | 0% |
| 2015 | 0.0c | 0% |
| 2016 | 0.0c | 0% |
| 2017 | 0.0c | 0% |
| 2018 | 0.0c | 0% |
| 2019 | 0.0c | 0% |
| 2020 | 0.0c | 0% |
| 2021 | 0.0c | 0% |
| 2022 | 0.0c | 0% |
| 2023 | 0.0c | 0% |
| 2024 | Sign Up Required | |
Adma Biologics Inc Optimized Dividend Chart
- Dividend Yield Today
- 0.0%
- Optimized Yield
- Sign Up Required
- 52 Week High
- 0.0% on 24 December 2023
- 52 Week Low
- 0.0% on 24 December 2023
- Next Ex-Div-Date Countdown
- Sign Up Required
About Adma Biologics Inc
ADMA Biologics, Inc. is a biopharmaceutical company. It develops, manufactures, and markets specialty plasma-based biologics for the treatment and prevention of infectious diseases. It is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its patients include immune-compromised individuals who suffer from an underlying immune deficiency disorder and immune-suppressed for medical reasons. Its product candidates include BIVIGAM, an Intravenous Immune Globulin (IVIG) product indicated for the treatment of Primary Humoral Immunodeficiency (PI); ASCENIV an IVIG product indicated for the treatment of PI, and Nabi-HB which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen (HBsAg). Its ADMA BioCenters subsidiary operates source plasma collection facilities in the United States. Its Plasma Collection Centers segment, provides a portion of its blood plasma for the manufacture of its products candidates.
- Sector
- Pharmaceuticals & Biotechnology
- Country
- United States
- Share Price
- $17.40 (yesterday's closing price)
- Shares in Issue
- 236 million
- Market Cap
- $4.1bn
- 0
- Market Indices
- none
